Bioverativ Inc. (BIVV) Begins Dosing in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease Mar 6, 2018 07:32AM
Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease Mar 6, 2018 07:30AM
Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A Feb 14, 2018 07:00AM
Bioverativ Reports Fourth Quarter and Full Year 2017 Performance Feb 13, 2018 04:15PM
Sanofi (SNY) Commences Tender Offer for Acquisition of Bioverativ (BIVV) Feb 8, 2018 06:23AM
View Older Stories

Feb 8, 2018 05:56AM Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
Feb 8, 2018 05:55AM Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
Jan 22, 2018 09:29AM Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
Jan 22, 2018 05:35AM Sanofi (SNY) to Acquire Bioverativ (BIVV) for $11.6B
Jan 22, 2018 01:10AM Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 22, 2018 01:04AM Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 22, 2018 01:00AM Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 16, 2018 04:15PM Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018
Jan 2, 2018 04:15PM Bioverativ to Present at the 2018 J.P. Morgan Healthcare Conference
Dec 22, 2017 04:05PM Bioverativ Announces 2018 Annual Meeting of Stockholders
Dec 11, 2017 02:48PM Bioverativ (BIVV) Announces Investigational BIVV009 Demonstrated Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in CAgD Patients
Dec 11, 2017 02:47PM Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients
Dec 11, 2017 10:07AM Bioverativ Inc. (BIVV) Reports New Data Showing Extended Prophylactic Dosing with ALPROLIX Provides Safe and Effective Protection in People with Severe Hemophilia B
Dec 11, 2017 10:02AM New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B
Dec 11, 2017 06:17AM Bioverativ Inc. (BIVV) Highlights Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
Dec 10, 2017 09:02AM Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A
Dec 9, 2017 09:02AM ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
Nov 27, 2017 07:32AM Bioverativ Inc. (BIVV) Granted Updated Labeling by FDA for ALPROLIX
Nov 27, 2017 07:30AM U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia B
Nov 21, 2017 04:15PM Bioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 1, 2017 04:00PM Bioverativ to Present at the Credit Suisse 2017 Healthcare Conference
Nov 1, 2017 09:40AM Bioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual Meeting
Oct 31, 2017 08:06AM Bioverativ Inc. (BIVV) Says Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE
Oct 31, 2017 08:00AM Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE®
Oct 26, 2017 04:15PM Bioverativ Reports Third Quarter 2017 Performance
Oct 2, 2017 07:35AM Sangamo Biosciences (SGMO) & Bioverativ Reports FDA Acceptance Of IND Application For ST-400
Oct 2, 2017 07:30AM Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia
Sep 28, 2017 10:30AM Bioverativ to Report Third Quarter 2017 Financial Results on October 26, 2017
Sep 6, 2017 05:44AM Bioverativ Inc. (BIVV) & Bicycle Therapeutics Announces Strategic Research Collaboration
Sep 6, 2017 02:00AM Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Haemophilia and Sickle Cell Disease
Sep 6, 2017 02:00AM Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia and Sickle Cell Disease
Aug 30, 2017 05:00PM Bioverativ to Present at Citi’s 12th Biotech Conference
Aug 24, 2017 07:30AM Bioverativ and Invicro Form Novel, Advanced Imaging Collaboration Focused on Improving Management of Joint Health in People with Hemophilia
Aug 2, 2017 04:31PM Bioverativ Reports Second Quarter 2017 Performance
Jul 7, 2017 07:00AM Bioverativ to Report Second Quarter 2017 Financial Results on August 2, 2017
Jul 6, 2017 07:05AM New Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care
Jul 6, 2017 07:00AM Bioverativ and Sobi Highlight Commitment to Improving Care for People with Hemophilia at ISTH 2017 Congress
Jun 28, 2017 04:00PM Bioverativ Completes Acquisition of True North Therapeutics
Jun 12, 2017 07:04AM Bioverativ (BIVV) Announces FDA Acceptance of Investigational NDA for BIVV001 to Treat Hemophilia A
Jun 12, 2017 07:00AM Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A
Jun 5, 2017 05:42PM Bioverativ to Present at the Jefferies 2017 Healthcare Conference
May 23, 2017 07:05AM Bioverativ Inc. (BIVV) to Acquire True North Therapeutics
May 23, 2017 07:00AM Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics
May 15, 2017 04:21PM Bioverativ Inc. (BIVV) Appoints Geno Germano to Board of Directors
May 15, 2017 04:18PM Bioverativ Appoints Geno J. Germano to Company’s Board of Directors
May 10, 2017 04:00PM Bioverativ to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 3, 2017 05:07PM Bioverativ Reports First Quarter 2017 Results
Apr 17, 2017 07:00AM Bioverativ Joins in Celebration of World Hemophilia Day
Apr 10, 2017 09:00AM Bioverativ Appoints Tim Harris Executive Vice President, Research and Development
Apr 6, 2017 09:31AM Bioverativ to Report First Quarter 2017 Financial Results on May 3, 2017
View Older Stories